Purple Biotech's IM1240 Selected for Oral Presentation at EORTC-NCI-AACR Symposium

REHOVOT, Israel, Oct. 29, 2026 /CourierPR/ -- Purple Biotech Ltd., a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer activity while minimizing toxicity, announced that an abstract on its lead tri-specific antibody, IM1240, has been selected for an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The presentation is scheduled for November 20, 2026, at 15:00 Central European Time (CET) in Barcelona, Spain.

The presentation is part of the symposium's Plenary Session 7: Proffered Papers, with the abstract number ENA26-0137.

IM1240 is part of Purple Biotech's CAPTN-3 platform, which is designed to simultaneously target tumors while engaging both T cells and NK cells. The platform's conditional CD3 masking approach is intended to confine immune activation to the tumor microenvironment, significantly expanding the therapeutic window compared to conventional T-cell engagers. The company is currently advancing IM1240 toward the clinic and plans to complete its IND-enabling work and, subject to regulatory clearance, initiate a first-in-human clinical study in 2027.

Purple Biotech's Interim Chief Executive Officer, Isaac Israel, expressed satisfaction with the selection of the abstract for a plenary session oral presentation.

The presentation will provide insights into the multi-arm mechanism of action of IM1240, including its engagement of NKG2A, as well as data on pharmacokinetic and safety evaluations. The company's second candidate, IM1305, is currently in preclinical development. Purple Biotech is headquartered in Rehovot, Israel, and its focus is on advancing its CAPTN-3 platform to develop next-generation immunotherapies.

The company's forward-looking statements are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements that are not statements of historical fact, and may be identified by words such as "believe," "expect," "intend," "plan," "may," "should," "could," "might," "seek," "target," "will," "project," "forecast," "continue," or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect the company's current views, expectations, beliefs, or intentions with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond the company's control, as well as uncertainties and other factors that may cause the actual results, performance, or achievements of the company to be significantly different from any future results, performance, or achievements expressed or implied by the forward-looking statements.

The presentation is planned to be available on the Purple Biotech website following the presentation at the symposium.